The implementation of antiretroviral therapy 23 years ago has rendered HIV infection
clinically manageable. However, the disease remains incurable, since it establishes latent …

The prokaryotic filamentous marine cyanobacteria are photosynthetic microbes that are
found in diverse marine habitats, ranging from epiphytic to endolithic communities. Their …

Proteolysis-targeting chimeras (PROTACs) are a powerful tool to hijack the endogenous
ubiquitin-proteasome system (UPS) and to degrade the intracellular proteins of therapeutic …

AIDS is a pandemic disease caused by HIV that affects 37 million people worldwide. Current
antiretroviral therapy slows disease progression but does not eliminate latently infected …

HIV-1 eradication strategies aim to achieve viral remission in the absence of antiretroviral
therapy (ART). The development of an HIV-1 cure remains challenging due to the latent …

Combinations of drugs that affect distinct mechanisms of HIV latency aim to induce robust
latency reversal leading to cytopathicity and elimination of the persistent HIV reservoir. Thus …

Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the
treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy. Despite …

HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection
with antiretroviral drugs alone. Latency reversing agents (LRAs) can activate HIV expression …

Bryostatins are a class of naturally occurring macrocyclic lactones with a unique fast
developing portfolio of clinical applications, including treatment of AIDS, Alzheimer's …

Although combination antiretroviral therapy (ART) has reduced mortality and improved
lifespan for people living with HIV, it does not provide a cure. Patients must be on ART for …